Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

21. Keratinocyte cancer (basal cell carcinoma and cutaneous squamous cell carcinoma)

Keratinocyte cancer (basal cell carcinoma and cutaneous squamous cell carcinoma) Clinical practice guidelines for keratinocyte cancer - Clinical Guidelines Wiki Skip Links Personal tools Search Navigation Cancer Council guidelines Bowel cancer Lung cancer Prostate cancer Skin cancer Methodology Hosted cancer guidelines Adolescents and Young Adult (AYA) guidelines Prevention Policies Social links Page actions The guideline recommendations were approved by the Chief Executive Officer (...) , and developed for health professionals practising in an Australian health care setting. This publication reflects the views of the authors and not necessarily the views of the Australian Government. Cite this guideline Cancer Council Australia Keratinocyte Cancers Guideline Working Party. Clinical practice guidelines for keratinocyte cancer. Sydney: Cancer Council Australia. [Version URL: , cited 2020 Feb 19]. Available from: . Please also see the following files: This is a wiki-based guideline. A PDF

2020 Cancer Council Australia

22. Lung Cancer Surveillance After Definitive Curative-Intent Therapy

Lung Cancer Surveillance After Definitive Curative-Intent Therapy Lung Cancer Surveillance After Definitive Curative-Intent Therapy: ASCO Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.02748 Journal of Clinical Oncology - published online before print December 12, 2019 PMID: Lung Cancer Surveillance After Definitive Curative-Intent Therapy (...) ; and , MD 17 x Nasser Altorki 1 University of Michigan Health System, Ann Arbor, MI 2 American Society of Clinical Oncology, Alexandria, VA 3 Erasmus Medical Center Cancer Institute, Rotterdam, the Netherlands 4 Wake Forest Health Science Center, Winston-Salem, NC 5 University of California Davis Comprehensive Cancer Center, Sacramento, CA 6 Yale University, New Haven, CT 7 University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 8 Princess Margaret Cancer Centre, University Health

2020 American Society of Clinical Oncology Guidelines

23. Molecular Biomarkers in Localized Prostate Cancer

Molecular Biomarkers in Localized Prostate Cancer Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLES Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.02768 Journal of Clinical Oncology - published online before print December 12, 2019 PMID: Molecular Biomarkers in Localized Prostate Cancer: ASCO Guideline , MD 1 x Scott E. Eggener ; , MSc 2 (...) of Medicine, Ann Arbor, MI 5 Las Vegas, NV 6 Royal Liverpool University Hospital, Liverpool, United Kingdom 7 Princess Margaret Cancer Center, University Health Network, Toronto, Ontario, Canada 8 Indiana University School of Medicine, Indianapolis, IN 9 Columbia University Irving Medical Center, New York, NY 10 University of Utah Health Care, Salt Lake City, UT 11 Cleveland Clinic, Cleveland, OH 12 Thomas Jefferson University, Philadelphia, PA 13 Dana-Farber Cancer Institute, Boston, MA S.E.E. and H.B

2020 American Society of Clinical Oncology Guidelines

24. Apalutamide (Erleada) - non-metastatic castration-resistant prostate cancer (NM-CRPC)

Apalutamide (Erleada) - non-metastatic castration-resistant prostate cancer (NM-CRPC) Published 10 February 2020 Statement of advice SMC2268 apalutamide 60mg film-coated tablets (Erleada®) Janssen-Cilag Ltd 10 January 2020 ADVICE: in the absence of a submission from the holder of the marketing authorisation apalutamide (Erleada®) is not recommended for use within NHSScotland. Indication under review: In adult men for the treatment of non-metastatic castration-resistant prostate cancer (NM-CRPC

2020 Scottish Medicines Consortium

25. ASTRO Guideline on Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin

ASTRO Guideline on Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin Practical Radiation Oncology (2019) Definitive and Postoperative Radiation Therapy for Basal and Squamous Cell Cancers of the Skin: An ASTRO Clinical Practice Guideline Anna Likhacheva, MD, MPH, a* Musaddiq Awan, MD, b Christopher A. Barker, MD, c Ajay Bhatnagar, MD, d Lisa Bradfield, e Mary Sue Brady, MD, f Ivan Buzurovic, PhD, g Jessica L. Geiger, MD, h Upendra Parvathaneni, MBBS (...) , i Sandra Zaky, MD, j and Phillip M. Devlin, MD, k a. Sutter Medical Center, Sacramento, CA, Department of Radiation Oncology and Task Force Vice Chair b. Medical College of Wisconsin, Milwaukee, WI, Department of Radiation Oncology c. Memorial Sloan Kettering Cancer Center, New York, NY, Department of Radiation Oncology d. Alliance Oncology, Casa Grande, AZ, Department of Radiation Oncology e. American Society for Radiation Oncology, Arlington, VA f. Memorial Sloan Kettering Cancer Center, New

2020 American Society for Radiation Oncology

26. A systematic review of the evidence for the efficacy of opioids for chronic non-cancer pain in community-dwelling older adults (Abstract)

A systematic review of the evidence for the efficacy of opioids for chronic non-cancer pain in community-dwelling older adults the ageing global population and concomitant increase in the use of opioid analgesia have highlighted the need to evaluate the effectiveness of opioids for chronic pain in older people.a systematic review of the evidence for the efficacy of opioids for chronic non-cancer pain in community-dwelling people aged 65 years or more was conducted using PRISMA guidelines (...) at baseline was associated with severe pain, severe impairment in activities of daily living and a diagnosis of depression. Fear of causing harm to older people was common amongst opioid prescribers, limiting prescription. Facilitators of opioid prescription included educational interventions and access to an evidence base for opioid use.there is limited evidence supporting the use of long-term opioid use in older people for chronic non-cancer pain and a lack of trials in this age group. Age-specific

2020 EvidenceUpdates

27. Prognostic significance of receptor discordance between primary and recurrent breast cancer associated with survival in patients with breast cancer: a meta-analysis

Prognostic significance of receptor discordance between primary and recurrent breast cancer associated with survival in patients with breast cancer: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2020 PROSPERO

28. Prevalence of incidental uterine cancer in autopsy studies: a systematic review to assess the potential for over diagnosis

Prevalence of incidental uterine cancer in autopsy studies: a systematic review to assess the potential for over diagnosis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

29. Prevalence of incidental findings of low dose computed tomography (LDCT) scans in lung cancer screening

Prevalence of incidental findings of low dose computed tomography (LDCT) scans in lung cancer screening Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

30. Prevalence of depression among patients with gastric cancer: a systematic review and meta-analysis

Prevalence of depression among patients with gastric cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2020 PROSPERO

31. Outdoor particulate matter exposure and lung cancer risk: a systematic review and meta-analysis based on individual outcome

Outdoor particulate matter exposure and lung cancer risk: a systematic review and meta-analysis based on individual outcome Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2020 PROSPERO

32. Outdoor particulate matter exposure and bladder cancer risk: a systematic review and meta-analysis

Outdoor particulate matter exposure and bladder cancer risk: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2020 PROSPERO

33. Optimal ovarian suppression duration for treatment of premenopausal patients with hormone receptor positive breast cancer: a meta-analysis and systematic review

Optimal ovarian suppression duration for treatment of premenopausal patients with hormone receptor positive breast cancer: a meta-analysis and systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

34. Is thrombocytosis associated with a particular subtype of lung cancer? A systematic review and meta-analysis.

Is thrombocytosis associated with a particular subtype of lung cancer? A systematic review and meta-analysis. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

35. Impact of using question prompt list on shared decision making in the cancer patient: a systematic review

Impact of using question prompt list on shared decision making in the cancer patient: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2020 PROSPERO

36. Impact of mental well-being in urological cancer outcomes

Impact of mental well-being in urological cancer outcomes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2020 PROSPERO

37. Night shift work and risk of breast cancer: meta-analysis of case-control, cohort and nested case-control studies

Night shift work and risk of breast cancer: meta-analysis of case-control, cohort and nested case-control studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2020 PROSPERO

38. Neoadjuvant therapy for pancreatic cancer surgery - which one is the best: a network meta-analysis

Neoadjuvant therapy for pancreatic cancer surgery - which one is the best: a network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2020 PROSPERO

39. Neoadjuvant chemotherapy versus primary debulking surgery in FIGO stage III and IV epithelial ovarian cancer: a systematic review and meta-analysis

Neoadjuvant chemotherapy versus primary debulking surgery in FIGO stage III and IV epithelial ovarian cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2020 PROSPERO

40. Lung cancer with combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis

Lung cancer with combined pulmonary fibrosis and emphysema: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2020 PROSPERO